<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Katia Pauwels</style></author><author><style face="normal" font="default" size="100%">Podevin, Nancy</style></author><author><style face="normal" font="default" size="100%">Didier Breyer</style></author><author><style face="normal" font="default" size="100%">Carroll, Dana</style></author><author><style face="normal" font="default" size="100%">Philippe Herman</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Engineering nucleases for gene targeting: safety and regulatory considerations.</style></title><secondary-title><style face="normal" font="default" size="100%">N Biotechnol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">N Biotechnol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Deoxyribonucleases</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Targeting</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">SAFETY</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 Jan 25</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">27</style></number><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">18-27</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Nuclease-based gene targeting (NBGT) represents a significant breakthrough in targeted genome editing since it is applicable from single-celled protozoa to human, including several species of economic importance. Along with the fast progress in NBGT and the increasing availability of customized nucleases, more data are available about off-target effects associated with the use of this approach. We discuss how NBGT may offer a new perspective for genetic modification, we address some aspects crucial for a safety improvement of the corresponding techniques and we also briefly relate the use of NBGT applications and products to the regulatory oversight.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/23851284?dopt=Abstract</style></custom1><section><style face="normal" font="default" size="100%">18</style></section></record></records></xml>